CanniMed Therapeutics: Acquiror or Target?
On November 14, 2017, Aurora Cannabis Inc. (Aurora) made a proposal to CanniMed Therapeutics Inc. (CanniMed) to acquire all of CanniMed's issued and outstanding common shares in a share exchange that valued CanniMed's common shares at a premium of almost 30 per cent over the previous day's share price. In its proposal, Aurora requested a response from CanniMed's board of directors by November 17, 2018, in the absence of which it intended to launch a formal, hostile takeover bid. Instead of responding to Aurora's offer, CanniMed's board of directors issued a news release advising shareholders to take no action regarding Aurora's bid and announcing that CanniMed had entered into an agreement to wholly acquire Newstrike Resources Inc. (Newstrike). As a result, Aurora took its bid directly to CanniMed shareholders, with a condition that CanniMed terminate the proposed Newstrike acquisition. Now CanniMed investors had to carefully consider their alternatives: should they tender their shares to Aurora's bid, or should they hold on to their shares according to the CanniMed board's recommendation and then decide whether to vote in favour of the Newstrike transaction?
【書誌情報】
ページ数:20ページ
サイズ:A4
商品番号:HBSP-W20422
発行日:2020/5/15
登録日:2021/2/19